1. Singh Gagandeep
2. Meenakshisundaram U
3. Pandian Jeyaraj Durai

9789390020683

10.5005/jp/books/18355_156

1/e

2020

2

1. Postgraduate Institute of Medical Education and Research, Chandigarh, India, All India Institute of Medical Science, New Delhi, India, Dayanand Medical College and Hospital, Ludhiana, Punjab, India, All India Institute of Medical Sciences, New Delhi, India, NIHR University College London Hospitals, Biomedical Research Centre, UCL Queen, Square Institute of Neurology, London, WC1N 3BG, & Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, United Kingdom; Dayanand Medical College, Ludhiana, Punjab, India, Dayanand Medical College and Hospital, Ludhiana, Punjab, India; Epilepsy, Institute of Neurology, Queen Square, London, United Kingdom, Dayanand Medical College and Hospital Ludhiana, Punjab, India; Institute of Neurology, Queen Square, London, United Kingdom, Dayanand Medical College and Hospital, Ludhiana, Punjab, India; Institute of Neurology, Queen Square, London, United Kingdom
2. Apollo Hospitals, Chennai, Tamil Nadu, India, SRM Institutes for Medical Science, Chennai, Tamil Nadu, India
3. Christian Medical College, Ludhiana, Punjab, India

Migraine, acute treatment, pathophysiology, calcitonin gene-related peptide, CGRP, randomized controlled trial, double-blind controlled trial, placebo-controlled trial, most bothersome symptom, MBS, physical examination